Market Research Logo

CAR T-cell Therapy for Multiple Myeloma – A Pipeline Analysis Report

CAR T-cell Therapy for Multiple Myeloma – A Pipeline Analysis Report

Chimeric antigen receptor (CAR) T-cell therapy for multiple myeloma: An insight

The CAR T-cell therapy for multiple myeloma pipeline analysis report includes ongoing clinical and non-clinical trends in the global CAR T-cell therapy for multiple myeloma.

Most of the pipeline therapeutics are in early stages of development; there is no CAR T-cell therapy approved to date for multiple myeloma treatment, but other treatments are available. A long-lasting and less-frequent dose can impact the overall multiple myeloma market.

In recent past, many pilot studies and early clinical trials have shown very promising results in the treatment of multiple myeloma with CAR T-cell therapy. However, the market has yet to witness the approval of the first CAR T-cell therapy for multiple myeloma, and it may take a few years from now. The currently available treatment for multiple myeloma include chemotherapy and other drugs, bisphosphonates, radiation, surgery, stem cell transplant, and plasmapheresis.

According to the National Cancer Institute (NIH), in 2017, there will be 30,280 new cases of myeloma and an estimated 12,590 deaths occur due to this disease in the US.

Covered in this report

The report covers the present scenario and the growth prospects of the car T-cell therapy for multiple myeloma. The report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.

Technavio's CAR T-cell Therapy for Multiple Myeloma – A Pipeline Analysis Report, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects during the forecast period. The report also includes a discussion of the key companies operating in this market.

Major companies

  • Juno Therapeutics
  • Kite Pharma
  • Novartis
  • Collectis
  • Key questions answered in this report
    • How will the market evolve during the forecast period?
    • What are the major parameters impacting the market?
    • What are the key market trends?
    • What are the challenges to market growth?
    • Who are the key companies in this market space?


    Press Release

    Technavio Announces the Publication of its Research Report - CAR T-cell Therapy for Multiple Myeloma – A Pipeline Analysis Report

    Technavio recognizes the following companies in the car T-cell therapy for multiple myeloma: Juno Therapeutics, Kite Pharma, Novartis, and Collectis.

    The “Chimeric antigen receptor (CAR) T-cell therapy for multiple myeloma - A pipeline analysis report, 2017”, provides comprehensive insights about pipeline molecules across this approach of treatment. The key objective of the report is to establish the understanding of all the pipeline molecules that fall under CAR T-cell therapy for multiple myeloma.

    This report provides information on the therapeutic development based on the CAR T-cell therapy for multiple myeloma dealing with all the pipeline drugs; comparative analysis at various stages covering Phase III, Phase II, Phase I/II, and pre-clinical; therapeutics assessment by monotherapy and combination products; and molecule type drug information. The report also covers the company’s information involved in the therapeutic development of the products. It also highlights the dormant products.

    CARs are also known as chimeric immunoreceptors, chimeric T-cell receptors, artificial T-cell receptors or CAR T. They are engineered receptors, which graft an arbitrary specificity onto an immune effector cell (T-cell). CAR T-cell therapy uses an individual's own cells and “re-engineers” them to fight cancer. It is a very complex treatment.

    Companies Mentioned

    Juno Therapeutics, Kite Pharma, Novartis, and Collectis.

    • Executive summary
    • Scope of the report
    • Research methodology
    • Chimeric antigen receptor (CAR) Tcell therapy for multiple myeloma: An insight
      • Introduction
    • Major regulatory authorities
      • US
        • Table Drug approval process by US FDA
      • Europe
      • Japan
      • Australia
      • China
    • Pipeline landscape
      • Table Pipeline molecules by vendors
      • Table Pipeline landscape
    • Comparative analysis
      • Table Pipeline molecules by numbers
      • Table Pipeline molecules by percentage
      • Mid-stage molecules (Phase II and I/II)
        • Table Overview: Tisagenlecleucel-T
        • Table Clinical Trials Description of Tisagenlecleucel-T (CTL019 T-cells)
        • Table Overview: LCAR-B38M
        • Table Clinical trials description
        • Table Overview: AUTO2
        • Table Clinical trials description of AUTO2
      • Early-stage molecules (Phase I and IND)
        • Table P-BCMA-101: Overview
        • Table Overview: CAR-T NKR-2
        • Table Clinical trials description of CAR-T NKR-2
        • Table Overview: CM-CS1
        • Table Clinical trials description of CM-CS1
        • Table Overview: EGFRt/BCMA-41BBz CAR T-cell
        • Table Clinical trials description of EGFRt/BCMA-41BBz CAR T-cell
        • Table Overview: bb2121
        • Table Clinical trials description of bb2121
        • Table Overview: KITE-585
        • Table Overview: T-007
      • Pre-clinical and discovery-stage molecules
        • Table Overview: KMA.CAR-T
        • Table Overview: MB-104 CS1 CAR
        • Table Overview: Compound CAR
        • Table Overview: UCART38
        • Table Overview: UCARTCS1
        • Table Overview: LMA.CAR-T
    • Indication analysis
      • Table Analysis by indication
      • Table Overview of indication
    • Therapeutic assessment by therapy
      • Therapeutic assessment based on therapy
        • Table Assessment of pipeline products by therapy
    • Therapeutic assessment by RoA
      • Therapeutic assessment based on RoA
        • Table Assessment by RoA
    • Therapeutic assessment by target
      • Table Assessment by target
    • Key companies
      • Active companies: Category and parameters
        • Table Percentage of the company for different tier category
        • Table Overview: Autolus 2017
        • Table Overview: bluebird bio 2017
        • Table Overview: Celyad 2016
        • Table Overview: Cellectis 2016
        • Table Overview: HaemaLogiX 2017
        • Table Overview: iCell Gene Therapeutics 2017
        • Table Overview: Juno Therapeutics 2017
        • Table Overview: Kite Pharma 2017
        • Table Overview: Mustang Bio 2017
        • Table Overview: Nanjing Legend Biotech 2017
        • Table Overview: Novartis 2017
        • Table Overview: Poseida 2017
        • Table Overview: TNK Therapeutics 2016
    • Appendix
      • List of abbreviations
    • Explore Technavio

    Download our eBook: How to Succeed Using Market Research

    Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

    Download eBook

    Share this report